ABSTRACT
The therapeutic utility of T cell transfers has been repeatedly demonstrated in the past in combination with certain anticancer drugs, in mice bearing experimental tumors. Regional immunity is characterized by regional specificities of effector cells and of regulatory mechanisms which also involves the participation of cells such as epithelial cells which are not usually construed as being strictly a part of the immune system. Several anticancer drugs have been found to have immunomodulating action expressed in specific effects on the immune system. Tumor-induced suppression of the immune system and tumor escape mechanisms represent important areas of investigations. Soluble tumor suppressor factors have been repeatedly reported to occur clinically and should be purified and characterized as possible targets of intervention. Modification of tumor cells has been already studied for a number of years in efforts to develop better vaccines.
